{"entity":{"id":"surufatinib","kind":"drug","name":"Surufatinib","aka":["sulfatinib","Sulanda"],"tldr":"Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours.","summary":"Surufatinib (Sulanda) was discovered and developed by HUTCHMED in Shanghai. The NMPA approved it in December 2020 for unresectable locally advanced or metastatic, well-differentiated, non-pancreatic neuroendocrine tumours (SANET-ep trial) and in June 2021 for pancreatic neuroendocrine tumours (SANET-p trial). A US application was withdrawn in 2022 after the FDA asked for a multi-regional trial.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of surufatinib","url":"https://clinicaltrials.gov/search?intr=surufatinib"}],"tags":["china","nmpa-approved"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["vegf","csf1r"],"drugs":[],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo China deep dive","editedOn":"2026-09-16"},"code":"HMPL-012","modality":"Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor","mechanism":"Blocks the VEGF and FGF receptors that build tumour blood vessels and the CSF1 receptor on tumour-associated macrophages, cutting the tumour's blood supply and its immune shelter at once.","approvals":[{"region":"CN","year":2020,"indication":"Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/surufatinib/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"csf1","kind":"target","name":"CSF1","route":"/targets/csf1/"},{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}],"trial":[{"id":"nct06361888","kind":"trial","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","route":"/trials/nct06361888/"},{"id":"nct06654947","kind":"trial","name":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","route":"/trials/nct06654947/"},{"id":"nct06708858","kind":"trial","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06708858/"},{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/"},{"id":"nct05988372","kind":"trial","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","route":"/trials/nct05988372/"},{"id":"nct06531291","kind":"trial","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","route":"/trials/nct06531291/"},{"id":"nct07469956","kind":"trial","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","route":"/trials/nct07469956/"}]}}